PBYI
Puma Biotechnology, Inc.
Price Chart
Latest Quote
$7.66
+0.10 (+1.32%)
Current Price
| Previous Close | $7.56 |
| Open | $7.60 |
| Day High | $7.87 |
| Day Low | $7.56 |
| Volume | 367,724 |
Stock Information
| Shares Outstanding | 50.90M |
| Total Debt | $15.95M |
| Cash Equivalents | $101.55M |
| Revenue | $227.18M |
| Net Income | $24.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $389.89M |
| P/E Ratio | 15.96 |
| EPS (TTM) | $0.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $304.30M |
| Sales | $227.18M |
| Income | $24.38M |
| Book/sh | $2.52 |
| Cash/sh | $2.00 |
| Employees | 179 |
Financial Ratios
| Quick Ratio | 2.14 |
| Current Ratio | 2.38 |
| Debt/Eq | 12.42 |
Returns & Margins
| ROA | 9.48% |
| ROE | 21.62% |
| Gross Margin | 74.46% |
| Operating Margin | -8.54% |
| Profit Margin | 10.73% |
Ownership
| Insider Ownership | 15.49% |
| Institutional Ownership | 77.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 21.89 |
| P/S | 1.72 |
| P/B | 3.03 |
Analyst Data
| Recommendation | none |
| Target Price | $5.00 |
Technical Indicators
| SMA20 | $7.16 |
| SMA50 | $7.26 |
| SMA200 | $6.14 |
| RSI | 62.86 |
| ATR | 0.2829 |
| Shares Float | 39.09M |
| Short Float | 8.77% |
| Short Ratio | 13.77 |
| Volatility | 1.21 |
| Rel Volume | 1.67 |
Performance History
| Week | +4.50% |
| Month | +9.59% |
| Quarter | +25.16% |
| 6 Months | +37.28% |
| YTD | +32.76% |
| Year | +125.29% |
| 3 Years | +117.61% |
| 5 Years | -29.53% |
| 10 Years | -77.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $7.66 | 367,724 |
| 2026-06-18 | $7.56 | 427,400 |
| 2026-06-17 | $7.23 | 210,100 |
| 2026-06-16 | $7.17 | 216,700 |
| 2026-06-15 | $7.07 | 177,400 |
| 2026-06-12 | $7.33 | 260,000 |
| 2026-06-11 | $7.23 | 174,800 |
| 2026-06-10 | $7.02 | 163,300 |
| 2026-06-09 | $7.05 | 169,500 |
| 2026-06-08 | $6.85 | 141,200 |
| 2026-06-05 | $7.03 | 172,100 |
| 2026-06-04 | $7.01 | 178,400 |
| 2026-06-03 | $6.81 | 226,200 |
| 2026-06-02 | $6.98 | 330,900 |
| 2026-06-01 | $7.12 | 226,500 |
| 2026-05-29 | $7.17 | 205,900 |
| 2026-05-28 | $7.24 | 191,300 |
| 2026-05-27 | $7.31 | 154,300 |
| 2026-05-26 | $7.27 | 223,900 |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
đ° Latest News
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
Zacks âĸ 2026-06-11T15:48:00Z
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
Simply Wall St. âĸ 2026-05-14T12:04:56Z
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
Simply Wall St. âĸ 2026-05-11T13:04:09Z
Puma (PBYI) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-08T20:14:48Z
Puma Biotechnology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T19:12:28Z
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Zacks âĸ 2026-05-08T16:03:00Z
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2026-05-07T23:05:04Z
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-04-08T15:30:02Z
US Market's Hidden Gems: 3 Undiscovered Small Caps with Strong Potential
Simply Wall St. âĸ 2026-04-07T17:33:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $58,157,000 | $64,404,000 | $62,682,000 | $55,093,000 |
| Cost Of Revenue | $58,157,000 | $64,404,000 | $62,682,000 | $55,093,000 |
| Total Revenue | $228,371,000 | $230,468,000 | $235,637,000 | $228,031,000 |
| Operating Revenue | $228,371,000 | $230,468,000 | $235,637,000 | $228,031,000 |
| Expenses | ||||
| Interest Expense | $6,622,000 | $12,452,000 | $13,330,000 | $11,592,000 |
| Total Expenses | $191,072,000 | $199,502,000 | $202,997,000 | $197,311,000 |
| Other Income Expense | $1,027,000 | $862,000 | $759,000 | $-19,484,000 |
| Other Non Operating Income Expenses | $1,027,000 | $862,000 | $759,000 | $-28,000 |
| Net Non Operating Interest Income Expense | $-2,544,000 | $-7,728,000 | $-10,725,000 | $-10,779,000 |
| Interest Expense Non Operating | $6,622,000 | $12,452,000 | $13,330,000 | $11,592,000 |
| Operating Expense | $132,915,000 | $135,098,000 | $140,315,000 | $142,218,000 |
| General And Administrative Expense | $71,209,000 | $80,682,000 | $88,427,000 | $89,978,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Net Interest Income | $-2,544,000 | $-7,728,000 | $-10,725,000 | $-10,779,000 |
| Interest Income | $4,078,000 | $4,724,000 | $2,605,000 | $813,000 |
| Normalized Income | $31,111,000 | $30,278,000 | $21,591,000 | $15,372,240 |
| Net Income From Continuing And Discontinued Operation | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Total Operating Income As Reported | $37,299,000 | $30,966,000 | $32,640,000 | $23,720,000 |
| Net Income Common Stockholders | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Net Income | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Net Income Including Noncontrolling Interests | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Net Income Continuous Operations | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Pretax Income | $35,782,000 | $24,100,000 | $22,674,000 | $457,000 |
| Interest Income Non Operating | $4,078,000 | $4,724,000 | $2,605,000 | $813,000 |
| Operating Income | $37,299,000 | $30,966,000 | $32,640,000 | $30,720,000 |
| Gross Profit | $170,214,000 | $166,064,000 | $172,955,000 | $172,938,000 |
| Special Income Charges | - | $0 | $-625,000 | $-19,456,000 |
| Per Share | ||||
| Diluted EPS | $0.61 | $0.62 | $0.45 | $0.00 |
| Basic EPS | $0.62 | $0.62 | $0.46 | $0.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-4,085,760 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $53,342,000 | $48,076,000 | $47,523,000 | $41,345,000 |
| Reconciled Depreciation | $10,938,000 | $11,524,000 | $11,519,000 | $9,840,000 |
| EBITDA (Bullshit earnings) | $53,342,000 | $48,076,000 | $47,523,000 | $21,889,000 |
| EBIT | $42,404,000 | $36,552,000 | $36,004,000 | $12,049,000 |
| Diluted Average Shares | $50,653,283 | $49,100,433 | $47,550,852 | $44,929,998 |
| Basic Average Shares | $50,011,485 | $48,648,701 | $47,134,331 | $44,674,501 |
| Diluted NI Availto Com Stockholders | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Tax Provision | $4,671,000 | $-6,178,000 | $1,083,000 | $455,000 |
| Provision For Doubtful Accounts | $-362,000 | $-519,000 | $881,000 | $0 |
| Research And Development | $62,068,000 | $54,935,000 | $50,382,000 | $52,240,000 |
| Selling General And Administration | $71,209,000 | $80,682,000 | $89,933,000 | $89,978,000 |
| Other Gand A | $32,264,000 | $43,561,000 | $48,082,000 | $51,999,000 |
| Salaries And Wages | $38,945,000 | $37,121,000 | $40,345,000 | $37,979,000 |
| Total Unusual Items | - | $0 | $-625,000 | $-19,456,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-625,000 | $-19,456,000 |
| Write Off | - | $0 | $625,000 | $0 |
| Restructuring And Mergern Acquisition | - | - | $0 | $7,000,000 |
| Other Special Charges | - | - | - | $19,456,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $88,948,000 | $40,994,000 | $-7,429,000 | $-49,002,000 |
| Total Assets | $216,302,000 | $213,333,000 | $230,528,000 | $222,059,000 |
| Total Non Current Assets | $53,616,000 | $65,675,000 | $74,343,000 | $87,778,000 |
| Other Non Current Assets | $2,733,000 | $2,273,000 | $4,615,000 | $4,660,000 |
| Non Current Prepaid Assets | $101,000 | $102,000 | $210,000 | $0 |
| Non Current Deferred Assets | $3,830,000 | $7,075,000 | $0 | - |
| Non Current Deferred Taxes Assets | $3,830,000 | $7,075,000 | $0 | - |
| Goodwill And Other Intangible Assets | $41,392,000 | $51,131,000 | $60,871,000 | $70,610,000 |
| Other Intangible Assets | $41,392,000 | $51,131,000 | $60,871,000 | $70,610,000 |
| Current Assets | $162,686,000 | $147,658,000 | $156,185,000 | $134,281,000 |
| Other Current Assets | $1,911,000 | $3,700,000 | $2,305,000 | $1,954,000 |
| Restricted Cash | $2,091,000 | $0 | - | $0 |
| Prepaid Assets | $1,987,000 | $2,258,000 | $3,024,000 | $4,457,000 |
| Inventory | $5,515,000 | $8,724,000 | $7,080,000 | $4,526,000 |
| Receivables | $53,654,000 | $32,011,000 | $47,837,000 | $42,270,000 |
| Accounts Receivable | $53,654,000 | $32,011,000 | $47,837,000 | $40,350,000 |
| Allowance For Doubtful Accounts Receivable | $0 | $-362,000 | $-881,000 | $0 |
| Gross Accounts Receivable | $53,654,000 | $32,373,000 | $48,718,000 | $40,350,000 |
| Cash Cash Equivalents And Short Term Investments | $97,528,000 | $100,965,000 | $95,939,000 | $81,074,000 |
| Cash And Cash Equivalents | $29,635,000 | $69,219,000 | $84,585,000 | $76,201,000 |
| Other Receivables | - | - | $652,000 | $1,920,000 |
| Debt | ||||
| Total Debt | $28,546,000 | $74,082,000 | $111,490,000 | $114,281,000 |
| Long Term Debt And Capital Lease Obligation | $4,709,000 | $23,213,000 | $72,693,000 | $110,141,000 |
| Current Debt And Capital Lease Obligation | $23,837,000 | $50,869,000 | $38,797,000 | $4,140,000 |
| Current Debt | $22,523,000 | $45,329,000 | $33,997,000 | - |
| Other Current Borrowings | $22,523,000 | $45,329,000 | $33,997,000 | - |
| Long Term Debt | - | $21,719,000 | $65,659,000 | $98,307,000 |
| Net Debt | - | - | $15,071,000 | $22,106,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $85,962,000 | $121,208,000 | $177,086,000 | $200,451,000 |
| Total Non Current Liabilities Net Minority Interest | $4,709,000 | $25,097,000 | $77,704,000 | $122,967,000 |
| Current Liabilities | $81,253,000 | $96,111,000 | $99,382,000 | $77,484,000 |
| Other Current Liabilities | $2,329,000 | $2,835,000 | $975,000 | $1,370,000 |
| Payables And Accrued Expenses | $40,913,000 | $30,063,000 | $49,331,000 | $60,006,000 |
| Payables | $5,056,000 | $5,509,000 | $6,889,000 | $6,440,000 |
| Accounts Payable | $5,056,000 | $5,509,000 | $6,889,000 | $6,440,000 |
| Other Non Current Liabilities | - | $1,763,000 | $4,890,000 | $5,435,000 |
| Equity | ||||
| Common Stock Equity | $130,340,000 | $92,125,000 | $53,442,000 | $21,608,000 |
| Total Equity Gross Minority Interest | $130,340,000 | $92,125,000 | $53,442,000 | $21,608,000 |
| Stockholders Equity | $130,340,000 | $92,125,000 | $53,442,000 | $21,608,000 |
| Gains Losses Not Affecting Retained Earnings | $36,000 | $6,000 | $-4,000 | $0 |
| Other Equity Adjustments | $36,000 | $6,000 | $-4,000 | - |
| Retained Earnings | $-1,283,775,000 | $-1,314,886,000 | $-1,345,164,000 | $-1,366,755,000 |
| Other | ||||
| Ordinary Shares Number | $50,408,023 | $49,105,834 | $47,646,787 | $46,345,660 |
| Share Issued | $50,408,023 | $49,105,834 | $47,646,787 | $46,345,660 |
| Tangible Book Value | $88,948,000 | $40,994,000 | $-7,429,000 | $-49,002,000 |
| Invested Capital | $152,863,000 | $159,173,000 | $153,098,000 | $119,915,000 |
| Working Capital | $81,433,000 | $51,547,000 | $56,803,000 | $56,797,000 |
| Capital Lease Obligations | $6,023,000 | $7,034,000 | $11,834,000 | $15,974,000 |
| Total Capitalization | $130,340,000 | $113,844,000 | $119,101,000 | $119,915,000 |
| Additional Paid In Capital | $1,414,074,000 | $1,407,000,000 | $1,398,605,000 | $1,388,358,000 |
| Capital Stock | $5,000 | $5,000 | $5,000 | $5,000 |
| Common Stock | $5,000 | $5,000 | $5,000 | $5,000 |
| Non Current Accrued Expenses | $0 | $121,000 | $121,000 | $7,391,000 |
| Long Term Capital Lease Obligation | $4,709,000 | $1,494,000 | $7,034,000 | $11,834,000 |
| Current Capital Lease Obligation | $1,314,000 | $5,540,000 | $4,800,000 | $4,140,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,174,000 | $12,344,000 | $10,279,000 | $11,968,000 |
| Current Accrued Expenses | $35,857,000 | $24,554,000 | $42,442,000 | $53,566,000 |
| Net PPE | $5,560,000 | $5,094,000 | $8,647,000 | $12,508,000 |
| Accumulated Depreciation | $-4,598,000 | $-7,868,000 | $-7,680,000 | $-7,426,000 |
| Gross PPE | $10,158,000 | $12,962,000 | $16,327,000 | $19,934,000 |
| Leases | $2,549,000 | $3,779,000 | $3,779,000 | $3,779,000 |
| Machinery Furniture Equipment | $2,236,000 | $4,604,000 | $4,756,000 | $4,793,000 |
| Buildings And Improvements | $5,373,000 | $4,579,000 | $7,792,000 | $11,362,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $960,000 | $783,000 | $567,000 | $186,000 |
| Work In Process | $1,343,000 | $758,000 | $820,000 | $2,661,000 |
| Raw Materials | $3,212,000 | $7,183,000 | $5,693,000 | $1,679,000 |
| Other Short Term Investments | $67,893,000 | $31,746,000 | $11,354,000 | $4,873,000 |
| Other Properties | - | $95,000 | $302,000 | $302,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $41,731,000 | $38,862,000 | $14,369,000 | $-22,827,000 |
| Operating Activities | ||||
| Operating Cash Flow | $41,802,000 | $38,918,000 | $27,009,000 | $-15,827,000 |
| Cash Flow From Continuing Operating Activities | $41,802,000 | $38,918,000 | $27,009,000 | $-15,827,000 |
| Operating Gains Losses | $4,000 | - | - | $1,000 |
| Investing Activities | ||||
| Capital Expenditure | $-71,000 | $-56,000 | $-12,640,000 | $-7,000,000 |
| Investing Cash Flow | $-36,188,000 | $-20,438,000 | $-19,125,000 | $7,104,000 |
| Cash Flow From Continuing Investing Activities | $-36,188,000 | $-20,438,000 | $-19,125,000 | $7,104,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-45,198,000 | $-33,846,000 | $0 | $12,223,000 |
| Cash Flow From Continuing Financing Activities | $-45,198,000 | $-33,846,000 | $0 | $12,223,000 |
| Net Other Financing Charges | $-888,000 | $-666,000 | - | $-277,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $12,500,000 |
| Net Common Stock Issuance | - | $0 | $0 | $12,500,000 |
| Common Stock Issuance | - | $0 | $0 | $12,500,000 |
| Other | ||||
| Repayment Of Debt | $-44,440,000 | $-33,330,000 | $0 | $0 |
| Interest Paid Supplemental Data | $5,818,000 | $10,769,000 | $11,628,000 | $10,319,000 |
| Income Tax Paid Supplemental Data | $1,524,000 | $1,218,000 | $737,000 | $384,000 |
| End Cash Position | $31,726,000 | $71,310,000 | $86,676,000 | $78,792,000 |
| Beginning Cash Position | $71,310,000 | $86,676,000 | $78,792,000 | $75,292,000 |
| Changes In Cash | $-39,584,000 | $-15,366,000 | $7,884,000 | $3,500,000 |
| Proceeds From Stock Option Exercised | $130,000 | $150,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $-44,440,000 | $-33,330,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-44,440,000 | $-33,330,000 | $0 | $0 |
| Long Term Debt Payments | $-44,440,000 | $-33,330,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-36,117,000 | $-20,382,000 | $-6,485,000 | $14,104,000 |
| Sale Of Investment | $72,024,000 | $55,848,000 | $17,328,000 | $18,940,000 |
| Purchase Of Investment | $-108,141,000 | $-76,230,000 | $-23,813,000 | $-4,836,000 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-12,500,000 | $-7,000,000 |
| Purchase Of Intangibles | $0 | $0 | $-12,500,000 | $-7,000,000 |
| Net PPE Purchase And Sale | $-71,000 | $-56,000 | $-140,000 | $0 |
| Purchase Of PPE | $-71,000 | $-56,000 | $-140,000 | $0 |
| Change In Working Capital | $-10,078,000 | $-3,535,000 | $-17,854,000 | $-44,496,000 |
| Change In Other Working Capital | $-1,805,000 | $-1,587,000 | $-1,195,000 | $-920,000 |
| Change In Other Current Liabilities | $-2,412,000 | $-1,267,000 | $-940,000 | $-921,000 |
| Change In Other Current Assets | $-165,000 | $821,000 | $1,517,000 | $-1,982,000 |
| Change In Payables And Accrued Expense | $12,701,000 | $-17,203,000 | $-7,134,000 | $-37,799,000 |
| Change In Accrued Expense | $13,154,000 | $-15,823,000 | $-7,583,000 | $-33,065,000 |
| Change In Payable | $-453,000 | $-1,380,000 | $449,000 | $-4,734,000 |
| Change In Account Payable | $-453,000 | $-1,380,000 | $449,000 | $-4,734,000 |
| Change In Prepaid Assets | $-325,000 | $1,000,000 | $820,000 | $2,367,000 |
| Change In Inventory | $3,209,000 | $-1,644,000 | $-2,554,000 | $2,583,000 |
| Change In Receivables | $-21,281,000 | $16,345,000 | $-8,368,000 | $-7,824,000 |
| Changes In Account Receivables | $-21,281,000 | $16,345,000 | $-8,368,000 | $-7,824,000 |
| Stock Based Compensation | $6,944,000 | $8,245,000 | $10,247,000 | $11,826,000 |
| Provisionand Write Offof Assets | $-362,000 | $-519,000 | $881,000 | $0 |
| Asset Impairment Charge | $0 | $0 | $625,000 | $0 |
| Deferred Tax | $3,245,000 | $-7,075,000 | $0 | - |
| Deferred Income Tax | $3,245,000 | $-7,075,000 | $0 | - |
| Depreciation Amortization Depletion | $10,938,000 | $11,524,000 | $11,519,000 | $9,840,000 |
| Depreciation And Amortization | $10,938,000 | $11,524,000 | $11,519,000 | $9,840,000 |
| Gain Loss On Sale Of PPE | $4,000 | $0 | $0 | $1,000 |
| Net Income From Continuing Operations | $31,111,000 | $30,278,000 | $21,591,000 | $2,000 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Other Non Cash Items | - | - | - | $7,000,000 |
Fetched: 2026-06-20